Cherry David A, Plummer John L, Gourlay Geoffrey K, Coates Kenneth R, Odgers Christine L
Pain Management Unit, Flinders Medical Centre, Bedford Park, South Australia 5042 Australia Department of Pharmacy, Flinders Medical Centre, Bedford Park, South Australia 5042 Australia.
Pain. 1995 Jul;62(1):119-121. doi: 10.1016/0304-3959(95)00010-P.
A double-blind multidose trial of the addition of ketamine (0-40 mg, i.m., 8 times per day) to intramuscular morphine therapy was undertaken in a 61-year-old man with chronic back pain related to osteoporosis who had received inadequate pain relief from anterior interbody fusion, dorsal column stimulation and morphine alone. The patient reported only mild side effects. Nausea, tiredness and well-being were not significantly influenced by the ketamine dose level. Visual analogue pain scores prior to each dose were not associated with the ketamine dose level, but pain scores 30 min after doses were significantly reduced in a dose-related manner. In addition, the amount of morphine used by the patient was significantly reduced as the ketamine dose increased. This patient experienced substantial benefit from the addition of ketamine to intramuscular morphine therapy.
对一名61岁患有与骨质疏松相关慢性背痛的男性患者进行了一项双盲多剂量试验，该患者此前接受前路椎间融合术、背柱刺激术及单独使用吗啡治疗后疼痛缓解不足，此次试验在肌肉注射吗啡治疗基础上加用氯胺酮（0 - 40毫克，肌肉注射，每日8次）。患者仅报告有轻微副作用。恶心、疲倦和舒适感并未受到氯胺酮剂量水平的显著影响。每次给药前的视觉模拟疼痛评分与氯胺酮剂量水平无关，但给药后30分钟的疼痛评分随剂量增加而显著降低。此外，随着氯胺酮剂量增加，患者使用的吗啡量显著减少。该患者在肌肉注射吗啡治疗中加用氯胺酮后获益显著。
